FinscoFinsco

Alnylam Pharmaceuticals (US.ALNY)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ALNY · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion85.8%↑
ROE27.4%↑
Cash Conversion107.2%→
D/E Ratio0.94↑
Gross Margin79.3%↓
US.ALNY (Alnylam Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion    85.8%    ↑
ROE               27.4%    ↑
Cash Conversion  107.2%    →
D/E Ratio          0.94    ↑
Gross Margin      79.3%    ↓
Key Metrics
US.ALNY (Alnylam Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 85.8% ↑
ROE 27.4% ↑
Cash Conversion 107.2% →
D/E Ratio 0.94 ↑
Gross Margin 79.3% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies